Dianne C. Whitfield Sells 2,315 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Dianne C. Whitfield sold 2,315 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $107,161.35. Following the transaction, the insider now owns 50,751 shares of the company's stock, valued at $2,349,263.79. The trade was a 4.36 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Tarsus Pharmaceuticals Stock Performance

Shares of Tarsus Pharmaceuticals stock traded up $2.39 during trading on Monday, hitting $52.36. 1,101,887 shares of the company's stock traded hands, compared to its average volume of 643,190. Tarsus Pharmaceuticals, Inc. has a 1 year low of $20.08 and a 1 year high of $57.28. The business has a 50-day simple moving average of $48.59 and a 200-day simple moving average of $45.64. The stock has a market capitalization of $2.01 billion, a P/E ratio of -13.74 and a beta of 1.05. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The firm had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. As a group, analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Remove Ads

Analyst Upgrades and Downgrades

Several analysts recently weighed in on TARS shares. Oppenheimer raised their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Jefferies Financial Group raised their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a report on Thursday, March 6th. HC Wainwright reiterated a "buy" rating and issued a $73.00 price target on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. Guggenheim reissued a "buy" rating and set a $78.00 price objective (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Finally, Barclays decreased their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Tarsus Pharmaceuticals has an average rating of "Buy" and an average price target of $63.67.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in TARS. Crowley Wealth Management Inc. bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at $25,000. GF Fund Management CO. LTD. bought a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth $44,000. R Squared Ltd purchased a new stake in Tarsus Pharmaceuticals during the fourth quarter valued at $53,000. Quarry LP bought a new position in Tarsus Pharmaceuticals in the fourth quarter valued at about $166,000. Finally, HighTower Advisors LLC purchased a new position in Tarsus Pharmaceuticals in the fourth quarter worth about $207,000. Institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.